Sanofi to receive an exclusive right of first negotiation for Ventyx’s CNS-penetrant NLRP3 inhibitor VTX3232SAN DIEGO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: VTYX) (“Ventyx”), a clinical-stage ...
H.C. Wainwright analyst Emily Bodnar maintained a Hold rating on Ventyx Biosciences (VTYX – Research Report) today and set a price target ...
Oppenheimer analyst Jeff Jones maintained a Buy rating on Ventyx Biosciences (VTYX – Research Report) today and set a price target of ...
Sanofi invests $27 million in Ventyx Biosciences at $3.8243 per share. The investment will fund VTX3232 trials for ...
What Factors Have Led to Ventyx Biosciences Inc (VTYX) Stock Trading -93.48% Below Its 52-Week High?
On Thursday, Ventyx Biosciences Inc (VTYX) stock saw a decline, ending the day at $2.36 which represents a decrease of $-0.03 or -1.26% from the prior close of $2.39. The stock opened at $2.43 and ...
Ventyx stock climbs 7% on signing a $27 million strategic investment agreement with Sanofi in exchange for granting exclusive ...
Ventyx Biosciences Inc (VTYX) stock saw a modest uptick, ending the day at $2.46 which represents a slight increase of $0.16 or 6.96% from the prior close of $2.3. The stock opened at $2.66 and ...
Shares of Ventyx Biosciences rose more than 20% in premarket trading after the clinical-stage biopharmaceutical company said it would receive a $27 million from France's Sanofi.
Ventyx (VTYX) stock jumped 8% on news that Sanofi (SNY) has made a $27M strategic investment in the company at an ...
The Sanofi equity investment means the Big Pharma will receive exclusive rights of first negotiation surrounding VTX3232, an ...
SAN DIEGO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback